基于真实世界“肺炎1号”治疗新型冠状病毒肺炎的临床研究  

A real-world clinical study of‘Pneumonia No.1’in the treatment of COVID-19

作　　者：王林群 巴元明[2,3,4] 李伟男 李鸣[2,3,4] 贺朝雄 胡刚明[5] 黄威 王文炳 袁清波[8] 柯南江 熊致力 李家忆 石丽君 吴俊松 徐浦铭 申敏艺 刘馥溧 孔文文 WANG Lin-qun;BA Yuan-ming;LI Wei-nan;LI Ming;HE Chao-xiong;HU Gang-ming;HUANG Wei;WANG Wen-bing;YUAN Qing-bo;KE Nan-jiang;XIONG Zhi-li;LI Jia-yi;SHI Li-jun;WU Junsong;XU Pu-ming;SHEN Min-yi;LIU Fu-li;KONG Wen-wen(Hubei University of Chinese Medicine,Wuhan 430061,China;Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430061,China;Affiliated Hospital of Hubei University of Chinese Medicine,Wuhan 430061,China;Hubei Academy of Traditional Chinese Medicine,Wuhan 430061,China;Hanchuan People's Hospital,Hanchuan 432300,China;Wuhan Third Hospital,Wuhan 430061,China;Huangshi Youse Hospital,Huangshi 435000,China;Yingcheng Hospital of Traditional Chinese Medicine,Xiaogan 432400,China;Daye Hospital of Traditional Chinese Medicine,Huangshi 435100,China)

机构地区：[1]湖北中医药大学第一临床学院,湖北武汉430061 [2]湖北省中医院,湖北武汉430061 [3]湖北中医药大学附属医院,湖北武汉430061 [4]湖北省中医药研究院,湖北武汉430061 [5]汉川市人民医院,湖北孝感432300 [6]武汉市第三医院,湖北武汉430061 [7]黄石有色医院,湖北黄石435000 [8]应城市中医医院,湖北孝感432400 [9]大冶市中医医院,湖北黄石435100

出　　处：《时珍国医国药》2023年第3期735-738,共4页Lishizhen Medicine and Materia Medica Research

基　　金：湖北省科学技术厅新型肺炎应急科技攻关项目(2020FCA007);第六批全国老中医药专家学术经验继承工作指导老师项目(国中医药人教发〔2017〕29号);湖北省中医院“昙华林名医”培养项目(鄂中医院字[2018]72号)。

摘　　要：目的观察“肺炎1号”治疗新型冠状病毒肺炎的临床疗效。方法选取新型冠状病毒肺炎患者,按照治疗方法,“肺炎1号”治疗组采用“肺炎1号”联合西医常规治疗,西医对照组采用西医常规治疗,观察两组患者治疗前后的临床分型、退热时间、核酸转阴时间、临床症状、实验室检查结果及肺部CT改善情况。结果共纳入237例患者,其中“肺炎1号”治疗组95例,西医对照组142例。在转重率方面,西医对照为16例(11.27%),其中6例由普通型转为重型,2例由普通型转为危重型,8例由重型转为危重型;“肺炎1号”治疗组1例(1.05%)由普通型转为重型。在死亡率方面,西医对照组为7例(4.9%),“肺炎1号”治疗组为0例。两组转重率、死亡率有显著性差异(P<0.05)。西医对照组退热时间为3(1,3.75)d,“肺炎1号”治疗组退热时间为1(1,2)d,两组退热时间有显著性差异(P<0.05);西医对照组新型冠状病毒核酸转阴时间为7(5,11)d,“肺炎1号”新型冠状病毒核酸转阴时间为5.5(2.25,9)d,两组新型冠状病毒核酸转阴时间有显著性差异(P<0.05)。两组症状积分治疗后两组均明显降低,且有显著性差异(P<0.05)。治疗后,两组淋巴细胞绝对值与治疗前比较显著升高,且有显著性差异(P<0.05)。两组肺部CT改善情况无显著性差异(P>0.05)。结论“肺炎1号”结合西医常规治疗对新型冠状病毒肺炎有较好的治疗作用,能够快速稳定病情,阻断轻型、普通型向重型、危重型转化;缩短退热时间和新型冠状病毒核酸转阴时间,明显改善患者临床症状;较好促进肺部炎症吸收;使用安全可靠。Objective To observe the clinical efficacy of‘Pneumonia No.1’in the treatment of COVID-19.Methods Patients with COVID-19 admitted were selected,according to the treatment,‘Pneumonia No.1’treatment group adopted‘Pneumonia No.1’with conventional western medicine therapy,the control group treated by routine western medicine,western medicine Clinical classification,antipyretic time,nucleic acid negative time,clinical symptoms,laboratory examination results and lung CT im-provement were observed before and after treatment in 2 groups.Results A total of 237 patients were enrolled,including 95 in the‘Pneumonia No.1’treatment group and 142 in the western medicine control group.In terms of weight conversion rate,16 cases(11.27%)of the control group were from normal type to severe type,2 cases from normal type to critical type,and 8 cases from severe type to critical type.One case(1.05%)in‘Pneumonia No.1’treatment group changed from normal type to severe type.In terms of mortality,7 cases(4.9%)were found in the control group of Western medicine and 0 cases in the treatment group of‘Pneumonia No.1’.There were significant differences in weight conversion rate and mortality between the two groups(P<0.05).The antipyretic time of the western control group was 3(1,3.75)days,and the antipyretic time of the‘Pneumonia No.1’treatment group was 1(1,2)days.The antipyretic time of the two groups was significantly different(P<0.05).The conversion time of coronavirus nucleic acid was 7(5,11)days in the western medicine control group,and 5.5(2.25,9)days in the‘Pneumonia No.1’novel.There was significant difference in the conversion time of coronavirus nucleic acid between the two groups(P<0.05).In symptom scores between the two groups were significantly reduced after treatment(P<0.05).After treatment,the absolute value of lymphocytes in the two groups increased significantly compared with that before treatment,and there was a significant difference(P<0.05).There was no significant difference between the trea

关 键 词：“肺炎1号” 新型冠状病毒肺炎 临床研究 中医药 

分 类 号：R259[医药卫生—中西医结合]